AI-Enabled Software as Medical Devices — Reshaping Regulatory Routes and Medicine
OVERVIEWBioSpace reports that AI-enabled Software as Medical Devices (SaMD) are reshaping both regulatory routes and the practice of medicine itself. The analysis examines how the integration of AI into software-based medical tools is forcing regulatory agencies worldwide to reconsider how they classify, evaluate, and monitor these products. Traditional SaMD regulation — established frameworks in the US, EU, and other jurisdictions — was designed for deterministic software that produces consistent outputs from defined inputs. AI-enabled SaMD, particularly tools using machine learning or generative AI, introduce variability, adaptability, and opacity that existing frameworks struggle to accommodate. Regulatory agencies including FDA, the European Medicines Agency, and others are in various stages of updating their SaMD guidance to address these characteristics. The clinical implications are equally significant: AI-enabled SaMD is changing diagnostic workflows, treatment planning, and clinical documentation in ways that blur the boundary between software tool and medical practice. As these tools become more capable and more integrated into care delivery, the question of who is responsible for their outputs — the software manufacturer, the deploying health system, or the individual clinician — becomes increasingly urgent and legally contested. ---
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.